Vaccinated Animals Generated a Broad Spectrum of Protective Antibodies Vaccine Induces Antibodies that are at Least as Protective as Palivizumab Palivizumab Competing Antibody Response from Vaccine Protects Against Both Homologous and Heterologous Disease Strains
GAITHERSBURG, Md., Oct.
Multiple T-cell engaging bispecific programs show potential as disease modifying treatments for acute myelogenous leukemia, B-cell lymphomas and leukemia, and multiple myeloma
Xencor designates its first bispecific antibody candidate, XmAb14045 an anti-CD123xCD3, for IND-enabling studies MONROVIA, Calif.
Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts
will be presented at the 56 th American Society of Hematology
(ASH) Annual Meeting and Exposition taking place in San Francisco,
California, December 6-9, 2014, highlighting the following:
“Antibody-drug conjugates represent an innovative and important
therapeutic approach to targeting cancer.
Genetics, Inc. (Nasdaq: SGEN) today presented data from two ongoing
phase 1 clinical trials evaluating SGN-CD19A, an antibody-drug conjugate
(ADC) in development for the treatment of B-cell malignancies, including
non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), at
the 56 th American Society of Hematology (ASH) Annual Meeting
and Exposition taking place in San Francisco, CA December 6-9, 2014.
Sign-up for Sorrento Therapeutics Announces Poster Presentations on its Anti-c-Met/PD-L1 Bispecific Antibodies and Anti-c-Met-Antibody Drug Conjugate at the 37th Annual San Antonio Breast Cancer Symposium investment picks
Sign-up for Data From Phase 2b Clinical Trial of Clazakizumab, an Anti-IL-6 Monoclonal Antibody for the Treatment of Active Psoriatic Arthritis, to be Presented at the American College of Rheumatology Annual Meeting investment picks
SAN FRANCISCO, CA and YAVNE, ISRAEL --
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.